Drugs / Surlorian
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04141670 | Aug 2020 → Dec 2022 | RYR1-related myopathy | RyCarma Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07560020 | Jul 2026 → Aug 2027 expected | RYR1-related myopathy | RyCarma Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05122975 | Aug 2023 → Apr 2024 | catecholaminergic polymorphic ventricular tachycardia 1 | RyCarma Therapeutics, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Surlorian | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07560020 ↗ |
| Known as | ARM210 | “The goal of the proposed project is to determine the safety and tolerability as well as the preliminary efficacy of a novel small molecule drug, S48168 (ARM210), for the...” NCT05122975 ↗ |
| Known as | Rycal dmd | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594418 ↗ |
| Known as | S48168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04141670 ↗ |
| Action | Restore | “A novel oral small molecule which is designed to repair leaky RYR1 channels” NCT04141670 ↗ |
| Modality | Small molecule | “A novel oral small molecule which is designed to repair leaky RYR1 channels” NCT04141670 ↗ |
| Route | Oral | “A novel oral small molecule which is designed to repair leaky RYR1 channels” NCT04141670 ↗ |
| Target | RYR1 | “A novel oral small molecule which is designed to repair leaky RYR1 channels” NCT04141670 ↗ |